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Correction: Insights from immuno- oncology: the Society for 
Immunotherapy of Cancer Statement on access to IL-6- 
targeting therapies for COVID-19
Ascierto PA, Fox B, Urba W, et al. Insights from immuno- oncology: the Society for 
Immunotherapy of Cancer Statement on access to IL-6- targeting therapies for 
COVID-19. J Immunother Cancer. 2020;8:e000878. doi: 10.1136/jitc-2020-000878
Since the online publication of this article, the authors have noticed the following 
errors:
1) The following authors were missing the middle initial in their name; Bernard A 
Fox, Walter J Urba, Julie R Brahmer, Daniel S Chen, Tanja D de Gruijl, F Stephen Hodi 
Jr, Howard L Kaufman, Michael T Lotze, Kim M Margolin, Francesco M Marincola. 
The author name Jon M Wigginton was also spelt incorrectly as Jon M Wiggington. The 
author list is shown below and has been updated in the article.
Paolo Antonio Ascierto,1 Bernard A Fox,2 Walter J Urba,2 Ana Carrizosa Anderson,3 
Michael B Atkins,4 Ernest C Borden,5 Julie R Brahmer,6 Lisa H Butterfield,7 Ales-
sandra Cesano,8 Daniel S Chen,9 Tanja D de Gruijl,10 Robert O Dillman,11 Charles G 
Drake,12 Leisha A Emens,13 Thomas F Gajewski,14 James L Gulley,15 F Stephen Hodi Jr,16 
Patrick Hwu,17 David Kaufman,18 Howard L Kaufman,19 Michael T Lotze,20 Douglas 
G McNeel,21 Kim A Margolin,22 Francesco M Marincola,23 Michael J Mastrangelo,24 
Marcela V Maus,25 David R Parkinson,26 Pedro J Romero,27 Paul M Sondel,28 Stefani 
Spranger,29 Mario Sznol,30 George J Weiner,31 Jon M Wigginton,32 Jeffrey S Weber33
2) Affiliations 1, 2, 3, 4, 5, 11, 14, 15, 16, 20, 21, 22, 26, 28 were incorrect and affilia-
tions 8, 32, 34 have been removed. The updated affiliation list is shown below and has 
been updated in the article.
1Istituto Nazionale Tumori IRCCS Fondazione 'G. Pascale', Naples, Italy
2Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USA
3Harvard Medical School, Boston, Massachusetts, USA
4Georgetown Lombardi Comprehensive Cancer Center, Washington DC, USA
5University of Wisconsin Clinical Cancer Center, Madison, Wisconsin, USA
6Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive 
Cancer Center, Baltimore, Maryland, USA
7Research, Parker Institute for Cancer Immunotherapy, San Francisco, California, USA
8ESSA Pharma Inc, Redwood City, California, USA
9IGM Biosciences Inc, Mountain View, California, USA
10Medical Oncology - Amsterdam University Medical Centers, Vrije Universiteit- 
Cancer Center Amsterdam, Amsterdam, The Netherlands
11AIVITA Biomedical, Inc, Irvine, California, USA
12Herbert Irving Comprehensive Cancer Center, Columbia University Medical 
Center, New York, New York, USA
13UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA
14Pathology and Medicine, Immunology and Cancer Program, University of Chicago, 
Chicago, Illinois, USA
15National Cancer Institute, Bethesda, Maryland, USA
16Dana Farber Cancer Institute, Boston, Massachusetts, USA
17University of Texas MD Anderson Cancer Center, Houston, Texas, USA
18Bill & Melinda Gates Medical Research Institute, Cambridge, Massachusetts, USA
19Immuneering Corp New York, New York, New York, USA
20University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
21Carbone Cancer Center, University of Wisconsin- Madison, Madison, Wisconsin, USA
22Medical Oncology, City of Hope National Medical Center, Duarte, California, USA
23Refuge Biotechnologies, Menlo Park, California, USA
24Thomas Jefferson Medical College, Philadelphia, Pennsylvania, USA
25Massachusetts General Hospital Cancer Center, Harvard Medical School, Massachu-
setts General Hospital, Boston, Massachusetts, USA
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26ESSA Pharma Inc, Palo Alto, California, USA
27Oncology, University of Lausanne, Lausanne, VD, Switzerland
28Pediatrics, University of Wisconsin Madison, Madison, Wisconsin, USA
29Massachusetts Institute of Technology Koch Institute for Integrative Cancer Research, 
Cambridge, Massachusetts, USA
30Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut, USA
31Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, Iowa, USA
32MacroGenics Inc, Rockville, Maryland, USA
33Laura and Isaac Perlmutter Comprehensive Cancer Center, NYU Langone Medical 
Center, New York, New York, USA
3) In the main text,
 ► The sentence ‘The hypoxia and profound inflammatory response associated with 
the pneumonitis observed with the severe acute respiratory virus coronavirus-2 
SARS- COV-2 virus…’ now reads ‘The hypoxia and profound inflammatory response 
associated with the pneumonitis observed with the SARS- CoV-2 virus…’
 ► The sentence ‘One possibility is to encourage the use of IL-6 or IL-6- receptor (IL- 
6R) blocking antibodies like tocilizumab (Actemra, Roche- Genentech), sarilumab 
(Kevzara, Regeneron) and siltuximab (Sylvant, EUSA Pharma)…’ now reads ‘One 
possibility is to encourage the use of IL-6 or IL-6- receptor (IL- 6R) blocking anti-
bodies like tocilizumab (ActemraTM, Roche- Genentech), sarilumab (KevzaraTM, 
Regeneron) and siltuximab (SylvantTM, EUSA Pharma)…’
 ► The sentence ‘…including tocilizumab and sarilumab for use on a compassionate 
basis to critically ill hospitalized COVID-19- infected patients during this extraor-
dinary situation’ now reads ‘…including tocilizumab and sarilumab for use on 
a compassionate basis to critically ill hospitalized SARS- CoV-2- infected patients 
during this extraordinary situation’
4) To acknowledge medical writing support, the acknowledgment section has been 
updated to read:
‘The authors thank the clinicians working tirelessly on the frontlines of the COVID-19 
pandemic. The authors also acknowledge SITC staff for their contributions including 
Sam Million Weaver, PhD for medical writing and editorial support and Angela Kilbert 
for project management and assistance. Additionally, the authors wish to thank the 
society for supporting the manuscript development.’
5) In the competing interests section:
 ► Bristol- Myers Squibb was spelt incorrectly as ‘Bristol- Myer Squibb’ and 
‘Bristol- Myers- Squibb’
 ► The initials for authors BF, JB, ACA, DC, TdG. HK, ML, FM, KM now read BAF, JRB, 
AC, DSC, TDG, HLK, MTL, FMM, KAM
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